Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 31,346 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study participants Clear all

Conditions: Smoking
Interventions: Web+Mobile, Web Only; Behavioral
Lead sponsor: Oregon Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 1,266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Breast Neoplasms, Neoplasm Metastasis
Interventions: LY4064809, Placebo, Ribociclib, Palbociclib, Abemaciclib, Anastrozole, Letrozole, Exemestane, Fulvestrant; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 132
States / cities: Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 112 more

Conditions: Colorectal Neoplasms
Interventions: Device Assisted Colonoscopy, Standard Colonoscopy; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hearing Loss, Sensorineural
Interventions: Remote Microphone; Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Breast Cancer, Breast Cancer Female
Interventions: Standard of Care: Docetaxel, Standard of Care: Cyclophosphamide, Function Assessment of Cancer Therapy (FACT) Surveys; Drug · Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 65 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Colitis, Ulcerative
Interventions: Ozanimod; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 85
States / cities: Dothan, Alabama • Chandler, Arizona • Gilbert, Arizona + 63 more

Conditions: Opioid Use Disorder
Interventions: Morphine, AZD4041, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Obesity
Interventions: Food Craving app, Sleep Coach app; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis
Interventions: Transcutaneous auricular vagus nerve stimulation, Sham device; Device
Lead sponsor: Northwell Health; Other
Eligibility: 3 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: New Hyde Park, New York • Philadelphia, Pennsylvania

Conditions: Prostatic Neoplasms
Interventions: Pembrolizumab, Enzalutamide, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 28
States / cities: Mobile, Alabama • Fullerton, California • Los Angeles, California + 25 more

Conditions: Metastatic Gastrointestinal Cancer, Physical Activity
Interventions: Physical Activity Program; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Dulaglutide (Reference), Dulaglutide (Test); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Oral Cancer
Interventions: Watercress Juice; Dietary Supplement
Lead sponsor: Georgetown University; Other
Eligibility: 20 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Systemic Lupus Erythematosus
Interventions: DZP, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 16 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 60
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more

Conditions: Alzheimer Disease
Interventions: Ketogenic Diet, Therapeutic Lifestyles Changes Diet; Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 50 Years to 90 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Fairway, Kansas

Conditions: Prostatic Neoplasms
Interventions: Niraparib+ Abiraterone acetate fixed dose combination (FDC), Abiraterone acetate (AA), Prednisone, Placebo FDC, Placebo AA; Combination Product · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 696 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 53
States / cities: Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more

Conditions: Insomnia, Sleep, Sleep Disturbance
Interventions: Activated Sleep Pad system (Frequen-ZZZ), Deactivated Sleep Pad system (Frequen-ZZZ); Device
Lead sponsor: Kunasan Inc.; Industry
Eligibility: 40 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: State College, Pennsylvania

Conditions: Stroke
Interventions: rTMS Over Contralateral Hemisphere of Premotor Cortex, rTMS Over Ipsilateral Hemisphere of Premotor Cortex, Control 1: rTMS Timed 400 ms After Movement-related EMG, Control 2: rTMS Over the Somatosensory Cortex, Control 3: Sham rTMS, Motor Training; Device · Other
Lead sponsor: Emory University; Other
Eligibility: 55 Years to 80 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Alzheimer Disease
Interventions: Reminiscence with digital storytelling, Social wellness with scrapbook or journal; Behavioral
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 65 Years and older
Enrollment: 206 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: Thyroid Gland Medullary Carcinoma
Interventions: Decision Aid, Questionnaire Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Fecal Incontinence
Interventions: fecal microbial transplantation (FMT); Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 50 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Overweight and Obesity
Interventions: Weight Loss Education, Sleep and Eating Routine; Behavioral
Lead sponsor: The Miriam Hospital; Other
Eligibility: 21 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Substance Use, Mental Health Issue, Opioid Use, Medication Assisted Treatment
Interventions: IMANI, Telehealth MAT, Traditional MAT plus Referral and Linkage; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 525 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 8
States / cities: Bridgeport, Connecticut • Hartford, Connecticut • New Britain, Connecticut + 1 more

Conditions: Juvenile Psoriatic Arthritis
Interventions: Secukinumab; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 11
States / cities: Loma Linda, California • Gainesville, Florida • Chicago, Illinois + 8 more

Search by objective public record fields.

Web and Mobile Smoking Cessation

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Outcomes of Disposable Distal Attachment Device (Endocuff and Transparent Plastic Cap) Assisted Colonoscopy

Remote Microphone Candidacy Study

Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide

An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice

A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.

The Sleep and Weight Study

taVNS for FRNS in Children

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

Physical Activity In Gastrointestinal Cancer

A Study of Dulaglutide in Healthy Participants

A Study of the Effects of PEITC on Oral Cells With Mutant p53

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Therapeutic Diets in Alzheimer's Disease

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

Frequen-ZZZ SleepPad Investigational Device POC

Premotor Cortex: A New Target for Stroke Motor Rehabilitation

Intergenerational Reminiscence and Digital Storytelling

Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers

Fecal Microbial Transplantation for the Treatment of Fecal Incontinence in Women

Sleep Plus Eating Routines for Weight Loss

Community Driven Substance Use Recovery for High Opioid Overdose Areas

Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).